Fotagliptin (SAL067) is a DPP-4 inhibitor under development for the treatment of type 2 diabetes. Like other DPP-4 inhibitors, it works by increasing endogenously produced GLP-1 and GIP.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.